ESMO 2024: Promising Results from Targeted Therapy in Solid Tumours
Tuesday, 17 September 2024, 03:33
Significant Findings from ESMO 2024
At ESMO 2024, a major breakthrough in oncology was revealed with targeted therapy showing substantial promise for patients with solid tumours. This therapy significantly improved overall response rate (ORR) and progression-free survival (PFS), providing vital new avenues for treatment.
Key Results of the Study
- Overall Response Rate (ORR): The data indicates a remarkable increase in ORR for those receiving targeted therapy.
- Long-Term Progression-Free Survival (PFS): Results showed extended PFS benefits, with many experiencing sustained benefits for over a year.
Such findings underscore the potential of targeted therapies to change treatment paradigms in solid tumours, supporting ongoing research and clinical trials in this area.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.